Biomarkers predictive of response to pembrolizumab in head and neck cancer

Biomarkers predictive of response to pembrolizumab in head and neck cancer

Abstract Background We performed an integrated biomarker evaluation in pembrolizumab‐treated patients with R/M HNSCC enrolled in KEYNOTE‐012 or KEYNOTE‐055. The relationship between biomarkers and HPV status was explored. Methods We evaluated PD‐L1 (combined positive score [CPS]), TMB, T‐cell‐inflam...

Full description

Bibliographic Details
Main Authors: David G. Pfister, Robert I. Haddad, Francis P. Worden, Jared Weiss, Ranee Mehra, Laura Q. M. Chow, Stephen V. Liu, Hyunseok Kang, Nabil F. Saba, Lori J. Wirth, Ammar Sukari, Erminia Massarelli, Mark Ayers, Andrew Albright, Andrea L. Webber, Robin Mogg, Jared Lunceford, Lingkang Huang, Razvan Cristescu, Jonathan Cheng, Tanguy Y. Seiwert, Joshua M. Bauml
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Cancer Medicine
Subjects:
biomarker
head and neck squamous cell carcinoma
immunotherapy
pembrolizumab
tumor microenvironment
tumor mutational burden
Online Access:https://doi.org/10.1002/cam4.5434

Internet

https://doi.org/10.1002/cam4.5434

Similar Items